Epigenetic and the discovery of analgesics is on the agenda at SMi’s Pain Therapeutic conference

March 25, 2011 - PRLog -- Pain affects all of us some of the time, and many of us all the time. Yet, the pharmacologic treatments available to alleviate pain have changed little in the last 50 years. Those who suffer from acute pain originating in the peripheral nervous system have the best chances of finding relief, while others suffering chronic neuropathic pain must often settle for partial or even minimal relief.

Now in its 11th year, SMi's annual Pain Therapeutic conference series has gone from strength to strength and this year's event seeks to address the current issues facing the Clinical R&D field of Pain drug development, and the challenges when taking a new drug from pre- to post-clinical trials.

Featuring 22 leading industry expert speakers, this CPD Accredited program addresses key areas such as:

•   Translational medicine in pain R&D
•   Clinical Target Validation: Increasing human evidence and confidence in support of target selection
•   Advanced human pain biomarkers in early drug development
•   Animal models of osteoarthritis (OA) pain
•   Early proof of concept trials in chronic pain - Practical considerations    

For more information and to down load the brochure visit www.smi-online.co.uk/2011pain24.asp or alternatively contact Zain Philbey  or telephone on +44 0 207 827 6722

# # #

Pain Therapeutics is just one of the many conferences that are a part of the SMi Group portfolio.

The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk